Acadia Pharmaceuticals gets U.S. patent allowance for trofinetide dosing
The allowance covers weight-banded dosing of trofinetide for Rett syndrome and is expected to extend U.S. protection to March 28, 2041, from July 2036.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Acadia Pharmaceuticals Inc. (ACAD) Patent Allowance Extends Trofinetide Protection to 2041
USPTO issued a Notice of Allowance for Acadia’s patent on weight-banded dosing of trofinetide, expected to protect DAYBUE in the U.S. through Mar 28, 2041, including six months pediatric exclusivity. Current method-of-use patent expires July 2036.Material DetailsContext by AI AnalystThis is a mid-c…